Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dirk Steinert

Internal Medicine Appleton, WI Medical Doctor

NPI 1033137294 CMS profile 648988

3925 N Gateway Dr, Appleton, WI 54913

Open in the dashboard

General payments

$12,094

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$39,247 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Dirk Steinert of Appleton, WI is reported in the CMS Open Payments database as having received $12,094 across 30 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $39,247 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,960 7
2024 General $2,291 8
2023 General $1,456 3
2022 General $3,365 7
2021 General $1,810 2
2020 General $14 1
2019 General $199 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dirk Steinert
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dirk Steinert were reported at $2,960. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dirk Steinert Internal Medicine median Middle half National median
2019 $199 $159 $48–$570 $163
2020 $14 $119 $33–$402 $114
2021 $1,810 $135 $37–$521 $132
2022 $3,365 $141 $42–$496 $149
2023 $1,456 $149 $45–$519 $160
2024 $2,291 $154 $47–$537 $164
2025 $2,960 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $8,229 17 payments
  2. GlaxoSmithKline, LLC. $1,750 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,319 2 payments
  4. AstraZeneca Pharmaceuticals LP $272 4 payments
  5. Novo Nordisk Inc $220 3 payments
  6. Medtronic, Inc. $153 1 payment
  7. Alexion Pharmaceuticals, Inc. $125 1 payment
  8. Abbott Laboratories $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,015 9 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,250 9 payments
  3. Food and Beverage $815 11 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS $3,560 9 payments
  2. SHINGRIX $1,750 1 payment
  3. JARDIANCE $1,305 1 payment
  4. NURTEC ODT $600 2 payments
  5. PAXLOVID $600 2 payments
  6. ENDURANT IIS $153 1 payment
  7. STRENSIQ $125 1 payment
  8. Saxenda $124 1 payment
  9. BRILINTA $109 2 payments
  10. FreeStyle Libre 3 $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

3,804

Median for Internal Medicine: 777

Drug cost

$892,655

Median for Internal Medicine: $73,373

Branded share of claims

82.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mresvia Rsv Vaccine, Pref, Mrna/Pf Brand 1,559 $490,271
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 1,050 $232,783
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 455 $137,819
Eliquis Apixaban Brand 31 $9,182
Breo Ellipta Fluticasone/Vilanterol Brand 13 $6,797
Sucralfate Generic 11 $2,004
Levetiracetam Generic 27 $1,326
Gabapentin Generic 50 $1,173
Atorvastatin Calcium Generic 58 $1,022
Clindamycin Phosphate Generic 12 $1,019

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$1,003,588

Of which drugs: $807,106

Medicare patients

3,002

Average age 83

Services billed

10,878

2,074 women, 928 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 59%
Alzheimer's or dementia 59%
Arthritis 56%
Chronic kidney disease 43%
Diabetes 38%
Ischemic heart disease 37%
Heart failure 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 2,182 2,182 $345,379
Pcv20 vaccine im 90677 Office 905 907 $264,705
Vaccine for influenza for injection into muscle 90662 Office 1,967 1,967 $160,821
Sarscv2 vac 30mcg trs-suc im 91320 Office 196 196 $25,182
Vaccine for influenza for injection into muscle 90653 Office 117 117 $9,573
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 54 54 $1,183

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $200
$200 31 —
NURTEC ODT
  • PFIZER INC. $200
$200 — —
PAXLOVID
  • PFIZER INC. $200
$200 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record